TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22672584
Drug: Immediately placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately placed implants in sockets with periapical pathology
Study: 22672584
Drug: Immediately placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately placed implants in sockets without periapical pathology (control group)
Study: 16984757
Drug: Artificial cycles
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial cycles with oral oestradiol and vaginal oestradiol if needed
Study: 31838256
Drug: Genetically-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically-guided therapy (Group G)
Study: 23652909
Drug: Isotretinoin therapy
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin therapy
Study: 26531051
Drug: Topical voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical voriconazole
Study: 14567768
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol plus intermittent medroxyprogesterone acetate (MPA)
Study: 15831776
Drug: N-desmethyl adinazolam
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-desmethyl adinazolam (NDMAD, 10 mg)
Study: 19840302
Drug: New baby
Normalized name: Little Remedies New Baby Essentials Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: New baby wipe formulation
Study: 12579547
Drug: Self-administered behavioral
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered behavioral treatment with written manuals
Study: 3412049
Drug: Binedaline with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binedaline with alcohol (0.8 g/kg)
Study: 30777570
Drug: Methylprednisolone injection
Normalized name: methylprednisolone Injection
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone injection (1 g in two 500 mg doses)
Study: 19486346
Drug: CNI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI treatment
Study: 8312826
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with zidovudine (AZT) alone
Study: 8312826
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with zidovudine (AZT)
Study: 3789208
Drug: transitional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: transitional treatment
Study: 21722003
Drug: control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: control treatment
Study: 26762247
Drug: Intraoral PBM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoral PBM treatment
Study: 23084379
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of venular width and arteriolar tortuosity
Study: 19202152
Drug: Oseltamivir (antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (antiviral agent)
Study: 17688919
Drug: Discontinuing low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Discontinuing low-dose aspirin (LDA)
Study: 17688919
Drug: Continuing low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuing low-dose aspirin (LDA)
Study: 17688919
Drug: Replacing LDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacing LDA with low-molecular-weight heparin
Study: 15184213
Drug: Ibuprofen (4-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (4-10 mg/kg)
Study: 15184213
Drug: Ibuprofen (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (5-10 mg/kg)
Study: 15184213
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and acetaminophen
Study: 9482142
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg sustained release verapamil
Study: 27802233
Drug: Multimodal Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal Cognitive Enhancement Therapy (MCET)
Study: 19858812
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (internal medicine residents only)
Study: 17826451
Drug: Pain-centered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain-centered treatment (PCT)
Study: 30464426
Drug: Passive finger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive finger exercises (25 minutes daily for 12 weeks)
Study: 20196970
Drug: 225 g
Normalized name: Sutab, 0.225 g-0.188 g-1.479 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 g of cold water prawns
Study: 7751527
Drug: Intranasal ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal ipratropium bromide (0.03%, 0.06%, and 0.12% dosage strengths); 2 sprays per nostril (total dose of 84, 168, and 336 micrograms)
Study: 7751527
Drug: Intranasal ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal ipratropium bromide (0.03% and 0.06% dosage strengths) in patients with perennial rhinitis
Study: 7751527
Drug: Intranasal ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal ipratropium bromide (0.06% dosage strength) in patients with the common cold
Study: 31621252
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Electroacupuncture + PNF)
Study: 25703961
Drug: Riociguat up
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riociguat up to 1.5 mg 3 times daily
Study: 23174368
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release (ER) niacin (1500 mg per day)
Study: 9071101
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg.kg‐1) with fentanyl (0.2 microgram.kg‐1)
Study: 9071101
Drug: Midazolam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.2 mg.kg‐1) with fentanyl (0.2 microgram.kg‐1)
Study: 9071101
Drug: Thiopental (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (5 mg.kg‐1) with fentanyl (0.2 microgram.kg‐1)
Study: 15522941
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate (MPA)
Study: 2939943
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate (MPA) after cross-over
Study: 31391104
Drug: Electroacupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture plus warm needling therapy (treatment group)
Study: 22382203
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (CJ) - double-strength Ocean Spray light CJ (2 × 230 ml) daily for 4 months
Study: 12709008
Drug: Skin whitening
Normalized name: ASCORBYL GLUCOSIDE 1.5 g in 1 mg BUCCAL EMULSION [skin whitening]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin whitening complex 5% cream
Study: 10906303
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment of small AAAs
Study: 10906303
Drug: Surgery after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery after conservative treatment
Study: 12150618
Drug: Topical budesonide
Normalized name: budesonide Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical budesonide
Study: 29653635
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg daily aspirin
Study: 24565347
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (50 μg and 100 μg)
Study: 16751657
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 10 mg per day for 2-7 days (Group A)
Study: 16751657
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg per day for 1 day and Vitamin K1 10 mg per day for 2-7 days (Group D)
Study: 15632893
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/day (aggressive lipid lowering)
Study: 16356804
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/day (moderate lipid lowering)
Study: 15374306
Drug: Pramiracetam (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramiracetam (600 mg twice a day)
Study: 25177815
Drug: Meldonium administered
Normalized name: meldonium
DrugBank: Meldonium (DB13723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meldonium administered at a dose of 1000 mg/ml intravenously in addition to controlled physical training (CPT) with intensity 80% for 2 weeks (10 SFI)
Study: 22920930
Drug: Prasugrel (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (5 mg daily)
Study: 9892520
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg daily)
Study: 23602770
Drug: Prasugrel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (10 mg daily)
Study: 18754820
Drug: 1.5 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mcg/kg fentanyl
Study: 16129547
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion (starting from 2 mIU/min, increasing every 30 min with 2 mIU/min increments up to 40 mIU/min)
Study: 31498862
Drug: Papaverine injection
Normalized name: papaverine Injection
DrugBank: Papaverine (DB01113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Papaverine injection
Study: 30565407
Drug: BioChaperone insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BioChaperone insulin Lispro (BCLIS)
Study: 29770541
Drug: sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 50 mg qd
Study: 27015624
Drug: Tramadol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1 mg/kg with 100 mL normal saline)
Study: 27015624
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 g intravenously)
Study: 27015624
Drug: Dexketoprofen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen (50 mg intravenously)
Study: 8965976
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 2 x 200 mg daily
Study: 2998219
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose fentanyl anaesthesia (0.01 mg/kg bw) - Group A
Study: 24880194
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve block (SSNB) with 10 mL 0.75% ropivacaine and axillary nerve block (ANB) with 10 mL saline
Study: 22301207
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine (0.5, 1.0, or 1.5 mg/kg) with placebo
Study: 12466788
Drug: High-dose dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dipyridamole infusion (0.70 mg/kg) followed by technetium 99m tetrofosmin (TF) injection (74 to 370 MBq)
Study: 7855555
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil (CP) 8 mg/kg/d b.i.d.
Study: 7855555
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (ACA) 40/10 mg/kg/d t.i.d.
Study: 4908340
Drug: Aerosol administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosol administration of influenza vaccine
Study: 4908340
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of A2/Hong Kong/68 virus vaccine
Study: 4908340
Drug: Bivalent (A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent (A2 and B) influenza virus vaccine
Study: 4908340
Drug: Single-dose immunization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose immunization
Study: 4908340
Drug: 2-dose immunization
Normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose immunization
Study: 27981743
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein isolate (WPI) 50 g
Study: 27981743
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (SPI) 50 g
Study: 25311146
Drug: Dexmedetomidine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.3 μg.kg(‐1)
Study: 18095967
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg.kg(‐1)
Study: 21444712
Drug: FV-100 200
Normalized name: HORSERADISH 10 g in 100 mL TOPICAL LIQUID [NWK A-FV]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FV-100 200 mg QD for 7 days
Study: 21444712
Drug: FV-100 800
Normalized name: HORSERADISH 10 g in 100 mL TOPICAL LIQUID [NWK A-FV]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FV-100 800 mg QD for 7 days
Study: 21444712
Drug: Single 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 400 mg dose of FV-100
Study: 21444712
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg QD dosing regimen for 7 days in elderly subjects
Study: 21444712
Drug: FV-100 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: FV-100 (all doses)
Study: 18192843
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine tabs
Study: 16455186
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg enteric‐coated tablet
Study: 12802644
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution (Group B)
Study: 30741682
Drug: Cerebral amyloid-β
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebral amyloid-β (Aβ) deposition measured by 11C Pittsburgh compound B (PIB) PET scan
Study: 29626614
Drug: Whole Body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Body Vibration (WBV) intervention (3.6‐11.6 g), 3 times per week for 6 months
Study: 10632642
Drug: Alosetron 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 2 mg b.d.
Study: 9768527
Drug: Alosetron 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 4 mg b.d.
Study: 10468696
Drug: Alosetron 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 8 mg b.d.
Study: 345889
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release theophylline preparation
Study: 30739369
Drug: Topical gaseous
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical gaseous ozone applied into periodontal pockets twice a week for 2 weeks during active periodontal therapy
Study: 25370147
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (40 IU/1 mL)
Study: 24835171
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 mg orally)
Study: 17613399
Drug: Basiliximab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20 mg on Day 0 and Day 4)
Study: 17613399
Drug: Anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-thymocyte globulin (ATG, 2.5 mg/kg/day for 3 to 5 days)
Study: 8130287
Drug: Group physical
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group physical therapy (weekly for 9 months)
Study: 2446574
Drug: Aprotinin (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (high doses to achieve plasma concentrations of more than 150 kallikrein inactivator units per milliliter)
Study: 29619453
Drug: Supervised exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exposure to one standard erythemal dose (SED; 100 J m‐2) of solar UV radiation three days per week for three weeks
Study: 20199828
Drug: Energy-protein supplements
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-protein supplements (40 g of protein and 400 kcal per day)
Study: 17469678
Drug: Newer disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer disease-modifying approaches such as immunotherapy
Study: 15670038
Drug: no GPIIb-IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: no GPIIb-IIIa antagonist (control)
Study: 11034258
Drug: Sirolimus (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (1 mg/m2)
Study: 11034258
Drug: Sirolimus (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (3 mg/m2)
Study: 11034258
Drug: Sirolimus (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (5 mg/m2)
Study: 24807871
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (OMP)
Study: 26512775
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol with sequential OMP
Study: 26512775
Drug: CEE/E/E2+cyclic OMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE/E/E2+cyclic OMP at 200 mg/day
Study: 9049690
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no tamoxifen treatment)
Study: 8447209
Drug: Doxapram 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram 1.8 mg.kg‐1.h‐1
Study: 28404108
Drug: 16 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 weeks of treatment with ombitasvir (25 mg), paritaprevir (150 mg), ritonavir (100 mg) plus weight-based ribavirin dosed twice daily
Study: 18245406
Drug: 24% oral
Normalized name: Entero VU, 24% oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% oral sucrose and pacifier
Study: 15871555
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart (BIAsp30)
Study: 10355516
Drug: Rebamipide (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (oral, 300 mg/day for 3 weeks starting 1 week before TAE)
Study: 7794594
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment with ambulatory and domiciliary care
Study: 7023307
Drug: Chenodiol 750
Normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodiol 750 mg/d
Study: 7023307
Drug: Chenodiol 375
Normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodiol 375 mg/d
Study: 31683467
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg for 15 min before incision, followed by 0.3‐0.5 μg/(kg·h) till the end of the operation)
Study: 22616830
Drug: DrotAA (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: DrotAA (24 μg/kg/hour) for 96 hours
Study: 22616830
Drug: DrotAA (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: DrotAA (24 μg/kg/hour) for 96 hours in patients with severe protein C deficiency
Study: 12757987
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin
Study: 17634053
Drug: Treatment Optimization
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Optimization Program (TOP) tool
Study: 16372518
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate (20 mg metal zinc)
Study: 9657654
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 1600 microg daily for 2 months
Study: 7814824
Drug: Eliprodil 30
Normalized name: Eliprodil
DrugBank: Eliprodil (DB12869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliprodil 30 mg
Study: 7814824
Drug: Midazolam 15
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 15 mg (positive control)
Study: 30229939
Drug: SQ tree
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ tree SLIT-tablet (12 DU)
Study: 22770920
Drug: 1200mg oral
Normalized name: FISH OIL 1200MG ORAL CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200mg oral gabapentin
Study: 20109575
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue 1 mg/kg
Study: 20109575
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue 3 mg/kg
Study: 20109575
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue 7 mg/kg
Study: 20109575
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (all doses)
Study: 20109575
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (high doses)
Study: 18664347
Drug: Tanreqing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanreqing injection (20 ml, once daily for 10 days)